Posted by Michael Wonder on 13 Nov 2019
Clovis Oncology announces reimbursement for Rubraca (rucaparib) tablets for women with relapsed ovarian cancer in Italy
13 November 2019 - Rucaparib now reimbursed in several countries in Europe with additional countries to follow in 2020.
Clovis Oncology today announced that the Italian Medicines Agency (AIFA) has approved rucaparib for reimbursement in Italy.
Rucaparib will soon be available as an option for monotherapy maintenance treatment for adults with relapsed, platinum-sensitive high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer that has responded to platinum-based chemotherapy.
